PExA AB (publ)
PExA AB (publ) develops and commercializes diagnostic products in various respiratory diseases. It offers its products for asthma, tuberculosis, cystic fibrosis, lung cancer, and chronic obstructive pulmonary diseases. The company's research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. It offers PExA 2.0, an instrum… Read more
PExA AB (publ) (FA0) - Net Assets
Latest net assets as of September 2025: €9.77 Million EUR
Based on the latest financial reports, PExA AB (publ) (FA0) has net assets worth €9.77 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.84 Million) and total liabilities (€2.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €9.77 Million |
| % of Total Assets | 82.51% |
| Annual Growth Rate | -27.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.45 |
PExA AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how PExA AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PExA AB (publ) (2021–2024)
The table below shows the annual net assets of PExA AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €8.23 Million | -37.78% |
| 2023-12-31 | €13.22 Million | -37.82% |
| 2022-12-31 | €21.27 Million | -2.91% |
| 2021-12-31 | €21.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PExA AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2251165000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €69.63 Million | 846.24% |
| Total Equity | €8.23 Million | 100.00% |
PExA AB (publ) Competitors by Market Cap
The table below lists competitors of PExA AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dangee Dums Limited
NSE:DANGEE
|
$2.05 Million |
|
Hanil Vacuum Co. Ltd
KQ:123840
|
$2.05 Million |
|
Hwa Tai Industries Bhd
KLSE:8478
|
$2.05 Million |
|
JABIL CIRCUIT - Dusseldorf Stock Exchang
DU:JBL
|
$2.05 Million |
|
Oxford Cannabinoid Technologies Holdings Plc
PINK:OCTHF
|
$2.05 Million |
|
JET CONTRACTORS
BC:JET-CONTRACTORS
|
$2.05 Million |
|
X2M Connect Ltd
AU:X2M
|
$2.05 Million |
|
Talis Biomedical Corp
PINK:TLIS
|
$2.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PExA AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,223,620 to 8,228,150, a change of -4,995,470 (-37.8%).
- Net loss of 10,162,729 reduced equity.
- New share issuances of 5,581,659 increased equity.
- Other factors decreased equity by 414,400.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.16 Million | -123.51% |
| Share Issuances | €5.58 Million | +67.84% |
| Other Changes | €-414.40K | -5.04% |
| Total Change | €- | -37.78% |
Book Value vs Market Value Analysis
This analysis compares PExA AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.04x to 0.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.48 | €0.02 | x |
| 2022-12-31 | €0.39 | €0.02 | x |
| 2023-12-31 | €0.24 | €0.02 | x |
| 2024-12-31 | €0.11 | €0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PExA AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -123.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1412.24%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.24x
- Recent ROE (-123.51%) is below the historical average (-60.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -35.42% | -358.97% | 0.08x | 1.20x | €-9.95 Million |
| 2022 | -20.24% | -71.43% | 0.24x | 1.17x | €-6.43 Million |
| 2023 | -60.83% | -399.14% | 0.13x | 1.14x | €-9.37 Million |
| 2024 | -123.51% | -1412.24% | 0.07x | 1.24x | €-10.99 Million |
Industry Comparison
This section compares PExA AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PExA AB (publ) (FA0) | €9.77 Million | -35.42% | 0.21x | $2.05 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |